Adalat and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Adalat (nifedipine), especially for people who are female, 60+ old, also take Aspirin, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Adalat. It is created by eHealthMe based on reports of 20,643 people who have side effects when taking Adalat from the FDA, and is updated regularly.

What is Adalat?

Adalat has active ingredients of nifedipine. It is often used in high blood pressure. eHealthMe is studying from 20,940 Adalat users. Check the latest studies of Adalat.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 538 drugs and 467 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

20,643 people reported to have side effects when taking Adalat.
Among them, 12 people (0.06%) have Second primary malignancy.

Could Adalat cause Second primary malignancy?

Among these 12 people:

What is the gender of people who have Second primary malignancy when taking Adalat? *

female: 70 %
male: 30 %

What is the age of people who have Second primary malignancy when taking Adalat? *

What are other drugs people take besides Adalat? *

What are other side effects people have besides Second primary malignancy? *

Diabetes: 5 people, 41.67%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 41.67%
Stress And Anxiety: 5 people, 41.67%
Fall: 5 people, 41.67%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 4 people, 33.33%
Urinary Tract Infection: 4 people, 33.33%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 4 people, 33.33%
Fatigue (feeling of tiredness): 4 people, 33.33%
Weakness: 3 people, 25.00%
Insomnia (sleeplessness): 3 people, 25.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 4 people, 33.33%
Varices Oesophageal (enlarged and swollen veins at the bottom of the oesophagus, near the stomach): 2 people, 16.67%
Prostate Cancer: 2 people, 16.67%
Primary Myelofibrosis (primary disorder of the bone marrow): 2 people, 16.67%
Pelvic Pain: 2 people, 16.67%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 2 people, 16.67%
High Blood Cholesterol: 2 people, 16.67%
Dry Eyes (lack of adequate tears): 2 people, 16.67%
Depression: 2 people, 16.67%
Carcinoid Tumor: 2 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Adalat and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adalat:

Adalat (20,940 reports)

Browse all side effects of Adalat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (538 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (467 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nifedipine (the active ingredients of Adalat) and Adalat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.